Wegovy-Fueled Q1 Beat Lifts Novo Nordisk's 2026 Outlook

Novo Nordisk beat Q1 estimates on strong Wegovy demand, posting $15.17 billion in revenue and $1.04 in adjusted EPS, and raised its 2026 outlook. The Wegovy pill launch contributed to early sales, with prescriptions surpassing 2 million since launch and more than $2.2 billion in first‑quarter Wegovy pill sales. Management now expects adjusted sales and operating profit to fall 4%–12% for the year, easing fears of a sharp slowdown in the obesity drug market, and the stock moved higher on the report.